|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.72 USD | -3.51% |
|
+8.94% | +37.44% |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,725 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 65.91% | - | - |
| Enterprise Value (EV) | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,725 | 2,725 | 2,725 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 65.91% | 0% | 0% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -4.1x | 19.9x | 17x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | - | - | - |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 1x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 4.06x | 3.75x | 3.2x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 4.06x | 3.75x | 3.2x |
| EV / EBITDA | -0x | -0x | -0x | -0x | 0x | -4.34x | 31.8x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -4.62x | 15x | 11x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -21.3x | 12.7x | 9.07x |
| FCF Yield | -5.8% | -7.63% | -7.93% | -3.41% | 21% | -4.7% | 7.84% | 11% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.613 | 0.5375 | 0.6317 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 671 | 727.2 | 851 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -627.8 | 85.62 | - |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -589.9 | 182.2 | 248.7 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -644.5 | 143.6 | 207.6 |
| Net Debt | -368.3 | - | 426.7 | 507.7 | - | - | - | - |
| Reference price 2 | 13.85 | 11.48 | 5.99 | 7.52 | 7.80 | 10.72 | 10.72 | 10.72 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 254,163 | - | - |
| Announcement Date | 23/02/22 | 21/02/23 | 26/02/24 | 24/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.25x | - | - | -.--% | 2.82B | |
| 34.48x | 8.66x | 26.88x | 0.05% | 56.71B | |
| 19.3x | 5.92x | 12.91x | 1.56% | 51.3B | |
| -44.07x | 14.64x | -42.66x | -.--% | 25.26B | |
| -18.66x | 4.56x | -7.99x | -.--% | 23.65B | |
| 23.4x | 4.6x | 12.02x | -.--% | 18.69B | |
| 24.3x | 4.84x | 15.77x | -.--% | 17.71B | |
| 52.96x | 24.1x | 62.06x | 0.07% | 17.7B | |
| -500.51x | 34.41x | -3836.85x | -.--% | 14.26B | |
| 17.65x | 5.13x | 11.97x | -.--% | 14.1B | |
| Average | -39.54x | 11.87x | -416.21x | 0.17% | 24.22B | |
| Weighted average by Cap. | -15.29x | 10.17x | -217.31x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
